Crescendo Biologics Appoints Dr Barbara Fleck as Head of Intellectual Property
Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…
read moreCrescendo Biologics is developing two proprietary platforms for biological therapeutics from the Babraham Institute: ribosome display for the optimization of antibodies and a transgenic mouse which produces heavy chain only antibodies.
Status current
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website www.crescendobiologics.com/
Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…
read moreAntibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus Cambridge, UK: 17…
read more16 October 2015 Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics,…
read more8 June 2011 Crescendo Biologics Limited (Crescendo) today announces the appointment of Matthew Roe as…
read moreUpdate your browser to view this website correctly.Update my browser now